Unique ID issued by UMIN | UMIN000032277 |
---|---|
Receipt number | R000036806 |
Scientific Title | The differecnces between SGLT2 and DPP4 inhibitors in blood glucose management and cardiac sympathetic nerve activity |
Date of disclosure of the study information | 2018/04/20 |
Last modified on | 2018/10/16 15:22:26 |
The differecnces between SGLT2 and DPP4 inhibitors in blood glucose management and cardiac sympathetic nerve activity
The differences between SGLT2 and DPP4 inhibitors in cardiac sympathetic nerve activity
The differecnces between SGLT2 and DPP4 inhibitors in blood glucose management and cardiac sympathetic nerve activity
The differences between SGLT2 and DPP4 inhibitors in cardiac sympathetic nerve activity
Japan |
Diabetes mellitus (DM) patients complicated with heart failure (HF)
Cardiology | Endocrinology and Metabolism |
Others
NO
The evaluation of blood glucose management and cardiac sympathetic nerve activity in patients with DM and HF
Safety,Efficacy
blood glucose management
cardiac sympathetic nerve activity
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
2
Treatment
Medicine |
If blood glucose management with patients who were administrated with DPP4 inhibitor were more bad, strict diet exercise therapy is performed and we add the dosage of DPP4 inhibitor.
This therapy will be continue for 6 months after the change, however, we stop this study if blood glucose manegement exacerbation will apear.
If blood glucose management with patients who were administrated with DPP4 inhibitor were more bad, strict diet exercise therapy is performed and we add SGLT2 inhibitor on DPP4 inhibitor.
This therapy will be continue for 6 months after the change, however, we stop this study if blood glucose manegement exacerbation will apear.
30 | years-old | <= |
90 | years-old | > |
Male and Female
Out patients with DM and HF of NHYA classification of I - III who are administrated with sitagliptin.
The dosage of sitagliptin does not change for 4 weeks or more.
Bloo d glucose management were worsening and patients who need to strict diet/exercise therapy or change medication.
Pregnancy, breast-feeding, patients who may be pregnant, and patients who want pregnancy during the study
Patients who may be thought to worse blood glucose management with the protocol of this study
Patients with moderate or severe renal impairment (less than eGFR45)
Patients with severe hepatic impairment (Child-Pugh classification C)
Patients who were judged inappropriate as subjects of this study by investigators
40
1st name | |
Middle name | |
Last name | Shunsuke Kiuchi |
Toho University Omori Medical Center
Department of Cardiovascular Medicine
6-11-1 Omorinishi, Ota-ku, Tokyo 143-8541
03-3762-4151
syunnsuke@med.toho-u.ac.jp
1st name | |
Middle name | |
Last name | Shunsuke Kiuchi |
Toho University Omori Medical Center
Department of Cardiovascular Medicine
6-11-1 Omorinishi, Ota-ku, Tokyo 143-8541
03-3762-4151
syunnsuke@med.toho-u.ac.jp
Toho University
Toho University Omori Medical Center, Department of Cardiovascular Medicine
Other
NO
2018 | Year | 04 | Month | 20 | Day |
Unpublished
Terminated
2017 | Year | 04 | Month | 27 | Day |
2017 | Year | 06 | Month | 01 | Day |
2018 | Year | 04 | Month | 16 | Day |
2018 | Year | 10 | Month | 16 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036806
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |